Latest Research And Development News

Temas Resources posted a CAD 2.63 million loss for H1 2026, driven by ramped-up exploration and RCL technology development, while securing $1.5 million in fresh funding and signing initial RCL licensing contracts.

BauMart Holdings has secured $244,463 through a placement of over 24 million shares at one cent each, aiming to bolster its BuildMart Modular operations and general working capital.

Anteris Technologies posted a $51.7 million loss in H1 2026 amid ramped-up R&D and clinical trial activity, supported by a $320 million capital raise and Medicare reimbursement for its DurAVR heart valve trial.

EBR Systems marked a commercial milestone with over 100 WiSE CRT implants and secured purchasing agreements with three major US healthcare networks. The company is progressing toward Medicare coverage and scaling manufacturing, supported by a near-complete A$150 million capital raise.

Vection Technologies has locked in $1.2 million in non-repayable government funding to advance four distinct R&D projects spanning AI, Extended Reality, digital health, and inclusive technology.

AVITA Medical posted robust Q2 2026 results with 18% revenue growth, driven by RECELL and supported by Cohealyx and PermeaDerm, and now expects to reach cash flow breakeven by year-end.

Ionic Rare Earths (ASX: IXR) has secured $8 million through a placement to back its Belfast Plant commercialisation and US growth plans, supported by a mix of domestic and international investors including a strategic US partner.

Environmental Clean Technologies (ASX: ECT) disclosed confidential talks on acquiring Xenica Materials and a new engineering deal with Metallium amid a price surge, followed by a $12 million placement announcement.

IperionX plans to relocate its parent company to Texas and list directly on Nasdaq, aligning its corporate structure with its US operations. The appointment of manufacturing veteran Michael J. Loparco aims to bolster the company’s industrial scale-up.

Clarity Pharmaceuticals bolsters its commercial readiness with a $178.3 million cash reserve and a key US manufacturing agreement, while clinical trials for its prostate cancer imaging and therapeutic agents progress with promising data.

Neurotech International has secured FDA clearance for its NTI164 Investigational New Drug application and obtained Notices of Allowance for two US patents, advancing its Phase 3 autism spectrum disorder program.

Spenda Limited has reshaped its business with significant cost cuts, divested non-core assets, and secured major shareholder backing, positioning itself for cash flow positive operations.